Augmented input from cardiac sympathetic afferents inhibits baroreflex in rats with heart failure

Lie Gao1, Harold D Schultz, Kaushik P Patel

  • 1Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, 985850 Nebraska Medical Center, Omaha, NE 68198-5850, USA.

Insights

In chronic heart failure, an overactive cardiac sympathetic afferent reflex (CSAR) inhibits the baroreflex. Blocking central AT1 receptors with losartan improved this baroreflex in heart failure rats.

Area of Science:

  • Cardiovascular Physiology
  • Autonomic Nervous System Regulation

Background:

  • The baroreflex is impaired in chronic heart failure (CHF).
  • Cardiac sympathetic afferent reflex (CSAR) activation inhibits the baroreflex.
  • CSAR is enhanced in CHF, linked to central angiotensin II (Ang II) mechanisms.

Purpose of the Study:

  • To test the hypothesis that augmented CSAR in CHF tonically inhibits the baroreflex via central AT1 receptors.

Main Methods:

  • Myocardial infarction-induced CHF or sham surgery in rats.
  • Anesthesia with alpha-chloralose and urethane, vagotomy.
  • Recordings of mean arterial pressure (MAP) and renal sympathetic nerve activity (RSNA).
  • Left ventricular epicardial application of capsaicin, electrical stimulation, or lidocaine.
  • Intracerebroventricular injection of losartan.

Main Results:

  • CSAR activation blunted baroreflex in both sham and CHF rats.
  • Lidocaine improved baroreflex in CHF rats.
  • Losartan improved baroreflex in CHF rats, indicating AT1 receptor mediation.

Conclusions:

  • Tonic cardiac sympathetic afferent input significantly contributes to baroreflex blunting in CHF.
  • This inhibition is mediated by central AT1 receptors.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...